These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18537673)

  • 1. A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's disease.
    Popoli P; Blum D; Domenici MR; Burnouf S; Chern Y
    Curr Pharm Des; 2008; 14(15):1500-11. PubMed ID: 18537673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease.
    Popoli P; Blum D; Martire A; Ledent C; Ceruti S; Abbracchio MP
    Prog Neurobiol; 2007 Apr; 81(5-6):331-48. PubMed ID: 17303312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics.
    Blum D; Hourez R; Galas MC; Popoli P; Schiffmann SN
    Lancet Neurol; 2003 Jun; 2(6):366-74. PubMed ID: 12849153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice.
    Martire A; Calamandrei G; Felici F; Scattoni ML; Lastoria G; Domenici MR; Tebano MT; Popoli P
    Neurosci Lett; 2007 Apr; 417(1):78-83. PubMed ID: 17331645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system.
    Chiang MC; Chen HM; Lai HL; Chen HW; Chou SY; Chen CM; Tsai FJ; Chern Y
    Hum Mol Genet; 2009 Aug; 18(16):2929-42. PubMed ID: 19443488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenosine receptors and Huntington's disease.
    Lee CF; Chern Y
    Int Rev Neurobiol; 2014; 119():195-232. PubMed ID: 25175968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington's disease models.
    Li W; Silva HB; Real J; Wang YM; Rial D; Li P; Payen MP; Zhou Y; Muller CE; Tomé AR; Cunha RA; Chen JF
    Neurobiol Dis; 2015 Jul; 79():70-80. PubMed ID: 25892655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrodia elata prevents huntingtin aggregations through activation of the adenosine A₂A receptor and ubiquitin proteasome system.
    Huang CL; Yang JM; Wang KC; Lee YC; Lin YL; Yang YC; Huang NK
    J Ethnopharmacol; 2011 Oct; 138(1):162-8. PubMed ID: 21924340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new drug design targeting the adenosinergic system for Huntington's disease.
    Huang NK; Lin JH; Lin JT; Lin CI; Liu EM; Lin CJ; Chen WP; Shen YC; Chen HM; Chen JB; Lai HL; Yang CW; Chiang MC; Wu YS; Chang C; Chen JF; Fang JM; Lin YL; Chern Y
    PLoS One; 2011; 6(6):e20934. PubMed ID: 21713039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remodeling of striatal NMDA receptors by chronic A(2A) receptor blockade in Huntington's disease mice.
    Martire A; Ferrante A; Potenza RL; Armida M; Ferretti R; Pézzola A; Domenici MR; Popoli P
    Neurobiol Dis; 2010 Jan; 37(1):99-105. PubMed ID: 19804830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease.
    Mievis S; Blum D; Ledent C
    Neurobiol Dis; 2011 Feb; 41(2):570-6. PubMed ID: 21062644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
    Domenici MR; Scattoni ML; Martire A; Lastoria G; Potenza RL; Borioni A; Venerosi A; Calamandrei G; Popoli P
    Neurobiol Dis; 2007 Nov; 28(2):197-205. PubMed ID: 17720507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional changes in postsynaptic adenosine A(2A) receptors during early stages of a rat model of Huntington disease.
    Orrú M; Zanoveli JM; Quiroz C; Nguyen HP; Guitart X; Ferré S
    Exp Neurol; 2011 Nov; 232(1):76-80. PubMed ID: 21867705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
    Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
    Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenosine A2A receptor antagonism increases nNOS-immunoreactive neurons in the striatum of Huntington transgenic mice.
    Cipriani S; Bizzoco E; Gianfriddo M; Melani A; Vannucchi MG; Pedata F
    Exp Neurol; 2008 Sep; 213(1):163-70. PubMed ID: 18586241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease.
    Tarditi A; Camurri A; Varani K; Borea PA; Woodman B; Bates G; Cattaneo E; Abbracchio MP
    Neurobiol Dis; 2006 Jul; 23(1):44-53. PubMed ID: 16651003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elucidating the role of the A2A adenosine receptor in neurodegeneration using neurons derived from Huntington's disease iPSCs.
    Chiu FL; Lin JT; Chuang CY; Chien T; Chen CM; Chen KH; Hsiao HY; Lin YS; Chern Y; Kuo HC
    Hum Mol Genet; 2015 Nov; 24(21):6066-79. PubMed ID: 26264576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists.
    Cristalli G; Lambertucci C; Marucci G; Volpini R; Dal Ben D
    Curr Pharm Des; 2008; 14(15):1525-52. PubMed ID: 18537675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant A2A receptor function in peripheral blood cells in Huntington's disease.
    Varani K; Abbracchio MP; Cannella M; Cislaghi G; Giallonardo P; Mariotti C; Cattabriga E; Cattabeni F; Borea PA; Squitieri F; Cattaneo E
    FASEB J; 2003 Nov; 17(14):2148-50. PubMed ID: 12958155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BDNF prevents NMDA-induced toxicity in models of Huntington's disease: the effects are genotype specific and adenosine A2A receptor is involved.
    Martire A; Pepponi R; Domenici MR; Ferrante A; Chiodi V; Popoli P
    J Neurochem; 2013 Apr; 125(2):225-35. PubMed ID: 23363456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.